Articles related to MYELODYSPLASTIC SYNDROMES

Luspatercept demonstrates superior efficacy in achieving transfusion independence for patients with low-risk MDS compared to traditional erythropoiesis-stimulating agents.

Imetelstat has shown promising results in improving the quality of life for MDS patients by significantly reducing transfusion dependency, a critical consideration in the management of this blood disorder.

Discover why CPX-351 extends relapse-free survival but does not significantly alter overall survival in younger AML/MDS patients, as revealed by the UK NCRI AML19 trial.

Enhance your clinical decision-making skills in the management of ESA-refractory LR-MDS. Register now for actionable insights and the latest research findings.

Luspatercept demonstrated superiority over epoetin alfa in improving red blood cell (RBC) transfusion independence in transfusion-dependent patients with lower-risk myelodysplastic syndromes (LR-MDS) who have not previously received erythropoiesis-stimulating agents (ESAs). These findings are part of a study that was presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting:

Nutritional challenges are common in older adults with acute leukemia (AML/MDS), and can have a significant impact on their quality of life and treatment outcomes. These challenges can be caused by a variety of factors, including the disease itself, its treatment, and the normal aging process. Some of the most common nutritional challenges in older adults with AML/MDS include appetite loss, weight loss, diarrhea, constipation, and mouth sores; physicians can provide nutritional interventions to help address these challenges and improve the quality of life for older adults with AML/MDS. These interventions may include nutrition counseling, meal planning, supplementation, and enteral nutrition.